

INDEX

CHAPTER- I INTRODUCTION		1 – 31
1	Introduction	1
1.1	Hot Melt Coating	1
1.2	Merits	2
1.3	Demerits	3
1.4	Applications	4
1.5	Hot Melt Coating Equipment	4
	1.5.1 Pan Coater	4
	1.5.2 Spouted Bed	5
	1.5.3 Fluidized Bed Coater	6
	1.5.4 Direct Blending	10
1.6	Hot Melt Coating Agents	11
	1.6.1 Challenges in Use of Lipids as HMC Agent	13
	1.6.2 Regulatory Issues in Use of Lipids as HMC Agent	14
1.7	Evaluation of Hot Melt Coating Agents	14
	1.7.1 Physical Characterization	15
	1.7.2 Chemical Characterization	18
1.8	Oral Solid Dosage Forms	25
	1.8.1 Merits of Multi-Unit Drug Delivery Systems	25
	1.8.2 Merits of Single Unit Dosage Forms	26
1.9	References	26
CHAPTER- II REVIEW OF LITERATURE		32 - 77
2	Review of Literature	32
2.1	Hot Melt Coating	32
2.2	Tenofovir	41
2.3	Sitagliptin	52
CHAPTER-III PLAN OF WORK		78 – 81
3.1	Rational of The Study	78
3.2	Plan of The Research Work	80

CHAPTER- IV AIM AND OBJECTIVE		82 - 88
4.1	AIM	82
4.2	Objectives	82
4.3	Quality Target Product Profile (QTPP)	82
4.4	Critical quality attributes	84
CHAPTER- V MATERIALS AND METHODS		89 – 129
5.1	Drug Profile: Tenofovir Disoproxil Fumarate (TDF)	89
	5.1.1 Determination of Organoleptic Properties (TDF)	91
	5.1.2 Particle Size Distribution (TDF)	91
	5.1.3 Density and Flow Properties (TDF)	91
	5.1.4 Solubility of Tenofovir Disoproxil Fumarate	92
	5.1.5 Melting point of TDF	93
	5.1.6 Loss on Drying of TDF	93
5.2	Risk Assessment for Drug Substance Attributes of TDF	93
5.3	Excipients for TDF	96
	5.3.1 Gelucire 43/01	96
	5.3.2 Precirol® ATO 5	97
	5.3.3 Microcrystalline Cellulose (Avicel PH 101)	99
	5.3.4 Spray Dried Lactose (DCL 11)	101
	5.3.5 Polyvinyl Pyrrolidone K-30	102
	5.3.6 Alpha- Tocopherol	105
	5.3.7 Magnesium Stearate	107
	5.3.8 Talc	108
	5.3.9 Crospovidone (CP)	109
	5.3.10 Silicified Microcrystalline Cellulose (PROSOLV)	111
	5.3.11 Mannitol	112
5.4	Drug Profile: Sitagliptin Phosphate Monohydrate	114
5.5	Risk Assessment for Drug Substance Attributes (SPM)	117
5.6	Coating Agent Profile	118
	5.6.1 Palmitic Acid	118
	5.6.2 Stearic Acid	120

5.7	Excipient Profile	122
	5.7.1 Dicalcium Phosphate	122
	5.7.2 Colloidal Silicon Dioxide (Aerosil)	125
	5.7.3 Polyethylene Glycol 4000	126
CHAPTER- VI EXPERIMENTAL WORK		130 - 184
6	Materials and Methods for Tenofovir Disoproxil Fumarate (TDF)	130
6.1	Materials and Equipment for TDF	130
6.2	Methods for TDF	132
	6.2.1 Preformulation Studies for TDF	132
	6.2.1.1 Organoleptic Properties of TDF	132
	6.2.1.2 Density and Flow Properties	132
	6.2.1.3 Solubility	132
	6.2.1.4 Melting Point	132
	6.2.1.5 UV-Visible Spectrophotometric Method Development	133
	6.2.1.6 Loss on Drying	134
	6.2.1.7 Excipient Compatibility Studies for TDF	134
6.3	Formulation Development for TDF	135
	6.3.1 Preparation of Drug Pellets for TDF	138
	6.3.1.1 Selection of Filler	138
	6.3.1.2 Selection of Binder	139
	6.3.1.3 Optimization of Fluid uptake	140
	6.3.1.4 Optimization of Screen Size for Preparation of Extrudes	141
	6.3.1.5 Optimization of Spheronization Process	142
	6.3.1.6 Optimization of Drying Process for Pellets	143
	6.3.1.7 Optimization of Pellet Size/Screen Size	144
	6.3.2 Hot Melt Coating of Pellets	144
	6.3.2.1 Optimization Hot Melt Coating Agent and Level of Coating	145

	6.3.2.2 Optimization of Coating Process Parameters: Pan Speed	147
	6.3.2.3 Optimization of Coating Process Parameters: Temperature	149
6.4	Evaluation of the Pellets	150
	6.4.1 Pellet appearance	150
	6.4.2 Mean Pellet Size (d_{mean})	150
	6.4.3 Bulk Density (ρ_b)	151
	6.4.4 Tapped Density (ρ_t)	151
	6.4.5 Carr Index (CI)	151
	6.4.6 Hardness and Friability	152
	6.4.7 Drug Content	152
	6.4.8 In-vitro Drug Release Study	153
	6.4.9 In-vitro Taste Evaluation	153
	6.4.10 Determination of Threshold Bitter Taste	154
	6.4.11 Taste Panel Method	154
	6.4.12 Stability Test	154
6.5	Compression of Tablets	154
6.6	Evaluation of Tablets	156
	6.6.1 Organoleptic Properties	156
	6.6.2 Weight Variation Test	156
	6.6.3 Tablet Hardness Test	157
	6.6.4 Thickness	157
	6.6.5 Tablet Friability	157
	6.6.6 Drug Content	158
	6.6.7 In-vitro Disintegration Test	158
	6.6.8 In-vitro Drug Release Study	158
	6.6.9 In-vitro Taste Evaluation	159
	6.6.10 Similarity Factor (f_2)	159
	6.6.11 Stability Test	160
6.7	Materials and Methods for Sitagliptin Phosphate Monohydrate	160

6.7.1	Materials and Equipment for SPM	160
6.7.2	Methods for SPM	161
6.7.2.1	Preformulation Studies for SPM	161
6.7.2.1.1	Organoleptic Properties	161
6.7.2.1.2	Melting Point	161
6.7.2.1.3	Identification (Fourier Transform Infrared (FTIR) Spectroscopy)	162
6.7.2.1.4	Spectrophotometric Method for Measurement of Sitagliptin	162
6.7.2.1.5	Solubility Analysis	163
6.7.2.1.6	Partition Coefficient	164
6.7.2.1.7	pH Determination	164
6.7.2.1.8	Loss on Drying (%)	164
6.7.2.2	Excipient Compatibility Studies	164
6.7.3	Formulation Development for Sitagliptin Phosphate Monohydrate	165
6.7.3.1	Process Selection	165
6.7.3.1.1	Initial Risk Assessment of the Process Variables	165
6.7.3.2	Selection of Filler	167
6.7.3.3	Selection of Disintegrant	168
6.7.3.4	Selection of Glidant and Lubricant	169
6.7.3.5	Preparations of SPM core tablets	169
6.7.3.6	Selection of coating agents	169
6.7.3.7	Physico-Chemical Properties of Tablets	171
6.7.3.7.1	Appearance	171
6.7.3.7.2	Hardness	171
6.7.3.7.3	Thickness	172
6.7.3.7.4	Percent Weight Gain	172
6.7.3.7.5	Weight Variation Test	172
6.7.3.7.6	Friability Test	173

	6.7.3.7.7 Disintegration Test	173
	6.7.3.7.8 In-vitro Dissolution Study of Marketed Products	173
	6.7.3.7.9 Drug Content	174
	6.7.3.7.9.1 Procedure for Assay of SPM Formulations	174
	6.7.3.7.10 Moisture Uptake	175
	6.7.3.7.11 Similarity Factor (f ₂):	175
	6.7.3.7.12 Stability Test	175
CHAPTER- VII RESULTS AND DISCUSSION		185 – 229
7	Results and Discussion	185
7.1	Preformulating Studie	185
	7.1.1 Organoleptic Properties of TDF	185
	7.1.2 Density and Flow Properties	185
	7.1.3 Solubility	185
	7.1.4 Melting Point	186
	7.1.5 Loss on Drying	187
7.3	Excipient Compatibility Studies	191
7.4	Preparation of Drug Pellets	192
	7.4.1 Selection of Filler	192
	7.4.2 Selection of Binder	193
	7.4.3 Optimization of Fluid Uptake	193
	7.4.4 Optimization of Screen Size for Preparation of Extrudes	194
	7.4.5 Optimization of Spheronization Process	194
	7.4.6 Optimization of Drying Process for Pellets	195
	7.4.7 Hot Melt Coating of Pellets	196
	7.4.7.1 Optimization Hot Melt Coating Agent and Level of coating	196
	7.4.7.2 Taste Evaluation	197

	7.4.7.3 Optimization of Coating Process Parameters: Pan Speed	199
	7.4.7.4 Optimization of Coating Process Parameters: Temperature	200
	7.4.7.5 Stability Evaluation	201
7.5	Compression of Tablets	203
7.6	In-vitro Dissolution Study	206
7.7	Taste Evaluation	207
7.8	Stability Evaluation	208
7.9	Preformulating Studies	211
	7.9.1 Organoleptic Properties	211
	7.9.2 Melting point	211
	7.9.3 Identification by Fourier Transform Infrared (FTIR) Spectroscopy	212
	7.9.4 UV Spectrophotometric Method for Measurement of SPM	213
	7.9.4.1 Estimation of the Absorption Maxima (λ_{max})	213
	7.9.4.2 Standard Graph of SPM in Distilled Water	213
	7.9.4.3 Standard Graph of SPM in 0.01 M Hydrochloric Acid	214
	7.9.4.4 Standard Graph of SPM in Phosphate Buffer pH 4.5	215
	7.9.4.5 Standard Graph of SPM in PB pH 8.0	216
	7.9.5 Solubility	218
	7.9.6 Partition Coefficient (K_o/w)	219
	7.9.7 pH of 2% Solution	219
	7.9.8 Loss on Drying (%)	219
7.10	Excipient Compatibility Studies	220
7.11	Formulation Development	221
	7.11.1 Selection of Filler	221
	7.11.2 Selection of Disintegrant	221

	7.11.3 Selection of Glidant and Lubricant	222
	7.11.4 Preparation of SPM Tablets	222
	7.11.5 Preparation of Coated SPM Tablets	223
7.12	Evaluation of SPM Coated Tablets	223
7.13	Stability Evaluation	226
CHAPTER- VIII CONCLUSIONS		230 - 232
PUBLICATIONS		
CERTIFICATES		